A modified Delphi exercise in physician-perceived risk factors for drug-induced pneumotoxicity in patients with rheumatological disease

• Published in: BMC pulmonary medicine 2024-10, Vol.24 (1), p.547-9, Article 547
• Main Authors: Cartlidge, Manjit K, Brown, Kevin K, Chaudhuri, Nazia, Corte, Tamera J, Dieudé, Phillipe, John, Levin, Kelly, Clive, Khanna, Dinesh, McRorie, Euan, Nicol, Lisa, Stewart, Gareth, Walsh, Simon L F, Wijsenbeek, Marlies, Hirani, Nik
• Format: Article
• Language: English
• Subjects: Aged; Antirheumatic agents; Antirheumatic Agents - adverse effects; Complications and side effects; Coronary artery disease; Delphi Technique; Development and progression; Diagnosis; Dosage and administration; Drug-induced interstitial lung disease; Drug-induced pneumotoxicity; Drugs; Emphysema; Female; Health aspects; Heart diseases; Humans; Interstitial lung disease; Likert scale; Lung diseases; Lung Diseases - chemically induced; Lung diseases, Interstitial; Lung Diseases, Interstitial - chemically induced; Male; Methotrexate; Middle Aged; Patients; Perceptions; Physicians; Pneumotoxicity; Pulmonologists; Questionnaires; Renal failure; Renal function; Rheumatic diseases; Rheumatic Diseases - drug therapy; Rheumatoid arthritis; Rheumatological drugs; Rheumatologists; Risk Assessment; Risk Factors; Rituximab; Smoking; Smoking - adverse effects; Variables
• ISSN: 1471-2466; 1471-2466
• DOI: 10.1186/s12890-024-03287-0

Drugs used to treat rheumatic disease are associated with pneumotoxicity (drug-induced lung disease), but little is known about associated risk factors. To determine expert physician-perceived risk factors for developing pneumotoxicity in patients with rheumatologic conditions. A modified international 3-tier Delphi exercise was performed. Tier 1 determined patient and drug variables that physicians perceive to be risk factors. Tier 2 determined degree of risk associated with the Tier-1 derived variables. Tier 3 aimed to internally validate and stratify exemplar cases into risk categories. 134 pulmonologists and 49 rheumatologists responded to Tier 1;157 physicians completed all tiers. Perceived risk factors included: drug type; history of previous pneumotoxicity; age; smoking; underlying rheumatic disease type and activity; renal function; pulmonary hypertension; left ventricular failure;presence, nature, severity and progression of pre-existing interstitial lung disease. Tier 2 data stratified these variables into risk profiles e.g. never versus current smoking was perceived as low and high risk respectively. An example of perceived high risk resulting from Tier 3 is a 75-year-old current smoker with high-activity rheumatoid arthritis (RA) with severe, progressive ILD being started on methotrexate. A perceived low risk is a 75-year-old currentsmoker with moderate-activity RA and emphysema with no cardiac or renal disease and no pre-existing ILD being started on rituximab. A risk prediction scoring tool is being developed to be used in validation studies. This modified Delphi exercise defined and stratified the perceived risk factors for developing pneumotoxicity. Age, current smoking, high underlying rheumatological disease activity, HRCT definite UIP and honeycombing, severity and progression of pre-existing ILD were perceived to be the highest risk-factors.